NICE Rejects Roche’s Avastin In Advanced Ovarian Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
The U.K.'s health care cost regulator says it wouldn't recommend Roche's Avastin as a first-line treatment for advanced ovarian cancer along with standard chemotherapy, on grounds it doesn’t offer value for money.
You may also be interested in...
NICE Rejects Avastin For Ovarian Cancer On Cost, Okays Lucentis
NICE has knocked back Avastin for ovarian cancer due to high cost, but Roche may have a plausible market strategy in place for the drug in the UK.
NICE Rejects Roche’s Avastin For Ovarian Cancer Due To Excessive Cost
Roche’s extremely high price for Avastin results in yet another knock-back by Britain’s NICE, this time for advanced ovarian cancer.
NICE Turns Down Avastin For Yet Another Indication In Draft Guidance
The U.K.’s NICE issues draft guidance recommending against use of Avastin for first recurrence of platinum-sensitive advanced ovarian cancer, citing evidence and cost-effectiveness issues.